Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | SCN1A | P35498 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653076 | 0.92 | HRH3 (0.74) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL16314629 | 0.90 | HRH3 (0.68) | NPC1RAB9AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL14577989 | 0.86 | NPC1 (0.69) | NPC1RAB9ALTA4HCA12CA1 | |
| SCHEMBL4517043 | 0.84 | PSMB1 (0.67) | LTA4HHRH3KDM4E | |
| SCHEMBL25975206 | 0.84 | PSMB1 (0.62) | LTA4HHRH3KDM4E | |
| SCHEMBL14084486 | 0.83 | NPC1 (0.66) | NPC1RAB9ALTA4HCA12CA1 | |
| SCHEMBL374497 | 0.83 | LTA4H (0.67) | NPC1RAB9ALTA4HCA12CA1 | |
| SCHEMBL1958165 | 0.83 | NPC1 (0.66) | NPC1RAB9ALTA4HCA12CA1 | |
| SCHEMBL2014076 | 0.83 | NPC1 (0.66) | NPC1RAB9ALTA4HCA12CA1 | |
| SCHEMBL19560190 | 0.83 | LTA4H (0.67) | NPC1RAB9ALTA4HCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-1732543-B1 | TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| EP-1791845-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006130160-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | NPC1 4177/4885RAB9A 2390/4885LTA4H 899/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | NPC1 3405/4885RAB9A 3931/4885LTA4H 1473/4885 |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | NPC1 565/4885RAB9A 3164/4885LTA4H 192/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | NPC1 3405/4885RAB9A 3931/4885LTA4H 1473/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | NPC1 565/4885RAB9A 3164/4885LTA4H 192/4885 |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | NPC1 565/4885RAB9A 3164/4885LTA4H 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.